Prime Medicine, Inc.
corporate_fare Company Profile
Prime Medicine, Inc. (NASDAQ:PRME) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PRME at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PRME spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Prime Medicine's Q3 10-Q Flags Going Concern Despite $134.7M Raise and 2027 Runway
- Prime Medicine Posts Q3 Loss, Pro-Forma Cash of $209.5M and Runway Through 2027
- Prime Medicine Posts $39M Q3 Operating Loss Days After $125M Raise
- Prime Medicine Prices $125M Offering at $3.50, a Discount to Monday's Close
- Prime Medicine Prices $125M Underwritten Stock Offering at $4.30 Reference
Financial Snapshot
Short Interest & Short Volume
4.80 days to coverFINRA reported short interest of 29,147,049 shares in PRME as of the October 30, 2026 settlement, a 11.3% decrease from the prior period — about 4.8 days to cover at its recent average daily volume. On November 20, 2026, 36.8% of PRME volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PRME, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.
Final Terms Confirm $125M Offering · Net Proceeds of $117.1 Million
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →